Results 21 to 30 of about 677,925 (163)

CircRERE promotes proliferation, migration and invasion of human multiple myeloma cell lines by regulating miR-128-3p/WEE1 axis [PDF]

Jichu yixue yu linchuang
Objective To investigate the impacts of circular RNA RERE (circRERE) on proliferation, migration and invasion of human multiple myeloma (MM) cell lines by regulating microRNA (miR)-128-3p/serine/threonine protein kinase (WEE1) axis. Methods Normal plasma
FANG Yuan, LI Yi, WANG Wei
doaj   +1 more source

Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer

, 2021
Wee1 inhibition has received great attention in the past decade as a promising therapy for cancer treatment. Therefore, a potent and selective Wee1 inhibitor is highly desirable.
Sunil Paliwal (1671400), Jiali Li (436886), Brant C. Boren (2462560), Hui Liu (33624), Peter Q. Huang (11313912), Ahmed A. Samatar (1720096), Aditya K. Unni (1820590), Sunny Abraham (1987135), Chad D. Hopkins (2178580), Sayee G. Hegde (2989284), Kevin D. Bunker (1309494)   +10 more
core   +2 more sources

The Apparent Requirement for Protein Synthesis during G2 Phase Is due to Checkpoint Activation

Cell Reports, 2020
Summary: Protein synthesis inhibitors (e.g., cycloheximide) block mitotic entry, suggesting that cell cycle progression requires protein synthesis until right before mitosis.
Sarah Lockhead, Alisa Moskaleva, Julia Kamenz, Yuxin Chen, Minjung Kang, Anay R. Reddy, Silvia D.M. Santos, James E. Ferrell, Jr.   +7 more
doaj   +1 more source

Chemotherapy-induced differential cell cycle arrest in B-cell lymphomas affects their sensitivity to Wee1 inhibition

Haematologica, 2018
Chemotherapeutic agents, e.g., cytarabine and doxorubicin, cause DNA damage. However, it remains unknown whether such agents differentially regulate cell cycle arrest in distinct types of B-cell lymphomas, and whether this phenotype can be exploited for ...
Xiaoguang Wang, Zhangguo Chen, Ameet K. Mishra, Alexa Silva, Wenhua Ren, Zenggang Pan, Jing H. Wang   +6 more
doaj   +1 more source

CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo

Haematologica, 2014
Novel combinations targeting new molecular vulnerabilities are needed to improve the outcome of patients with acute myeloid leukemia. We recently identified WEE1 kinase as a novel target in leukemias.
Leena Chaudhuri, Nicole D. Vincelette, Brian D. Koh, Ryan M. Naylor, Karen S. Flatten, Kevin L. Peterson, Amanda McNally, Ivana Gojo, Judith E. Karp, Ruben A Mesa, Lisa O. Sproat, James M. Bogenberger, Scott H. Kaufmann, Raoul Tibes   +13 more
doaj   +1 more source

A haploid genetic screen identifies the G1/S regulatory machinery as a determinant of Wee1 inhibitor sensitivity [PDF]

, 2015
The Wee1 cell cycle checkpoint kinase prevents premature mitotic entry by inhibiting cyclin-dependent kinases. Chemical inhibitors of Wee1 are currently being tested clinically as targeted anticancer drugs. Wee1 inhibition is thought to be preferentially
Floris Foijer, Bisteau, Xavier, Xavier Bisteau, Philipp Kaldis, Marcel A. T. M. van Vugt, Heijink, Anne Margriet, Matsushita, Felipe Yu, Blomen, Vincent A., Vincent A. Blomen, van Vugt, Marcel A. T. M., Anne Margriet Heijink, Blomen, Vincent VA, van Vugt, Marcel A. T. M.; id_orcid, Felipe Yu Matsushita, Foijer, Floris; id_orcid, van Vugt, Marcel A T M MA, Foijer, Floris, Kaldis, Philipp, Fabian Degener, Degener, Fabian   +19 more
core   +1 more source

Kinome-wide RNAi screening for mediators of ABT-199 resistance in breast cancer cells identifies Wee1 as a novel therapeutic target

, 2021
Antiapoptotic and proapoptotic BCL-2 protein family members regulate mitochondrial apoptotic pathway. Small molecule inhibitors of antiapoptotic BCL-2 proteins including BCL-2-specific inhibitor ABT-199 (Venetoclax) are in clinical development ...
Aka, Yeliz, Acikbas, Ufuk, Gül, Özgür, Kütük, Özgür, Başağa, Hüveyda, Karakaş, Bahriye, Bahriye Karakas, Ozgur Kutuk, Huveyda Basaga, Ozgur Gul, Yeliz Aka, Ufuk Acikbas   +11 more
core   +2 more sources

G2 checkpoint targeting via Wee1 inhibition radiosensitizes EGFRvIII-positive glioblastoma cells

Radiation Oncology, 2023
Background The gene of the Epidermal growth factor receptor (EGFR) is one of the most frequently altered genes in glioblastoma (GBM), with deletions of exons 2–7 (EGFRvIII) being amongst the most common genomic mutations.
Meryem H. Cetin, Thorsten Rieckmann, Konstantin Hoffer, Britta Riepen, Sabrina Christiansen, Fruzsina Gatzemeier, Simon Feyerabend, Melanie Schoof, Ulrich Schüller, Cordula Petersen, Martin Mynarek, Kai Rothkamm, Malte Kriegs, Nina Struve   +13 more
doaj   +1 more source

WEE1-mediated regulation of preMPF and MPF oscillations.

, 2020
(A) Approximated steady-state protein levels from studies by Ovejero et al. [8] using immunoblot analysis for CDK1T, CCNB1T, WEE1T and CDK1P Y15 (i.e. preMPF) in WEE1-expressing U2OS cells following release from synchronization in M phase.
Scott S. Terhune (8677500), Ranjan K. Dash (6688577), Katie M. Cataldo (8677506), Yongwoon Jung (8677503)   +3 more
core   +1 more source

Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer

npj Breast Cancer, 2023
Novel therapeutic strategies that can effectively combine with immunotherapies are needed in the treatment of triple-negative breast cancer (TNBC). We demonstrate that combined PARP and WEE1 inhibition are synergistic in controlling tumour growth in ...
Zhi Ling Teo, Mark J. O’Connor, Stephanie Versaci, Kylie A. Clarke, Emmaline R. Brown, Luke W. Percy, Keilly Kuykhoven, Christopher P. Mintoff, Peter Savas, Balaji Virassamy, Stephen J. Luen, Ann Byrne, Sneha Sant, Geoffrey J. Lindeman, Phillip K. Darcy, Sherene Loi   +15 more
doaj   +1 more source